Sirolimus News and Research

RSS

New clinical trial examines potential role of drug combination therapy to eliminate LAM cells

Researchers at the University of Cincinnati begin a new clinical trial this fall, examining the potential role of a drug combination therapy to eliminate lymphangioleiomyomatosis (LAM) cells.

7 Aug 2017

UC scientists take different approach to investigating how influenza spreads through the lungs

Influenza is a recurring global health threat that, according to the World Health Organization, is responsible for as many as 500,000 deaths every year, most due to influenza pneumonia, or viral pneumonia.

25 Jul 2017

OrbusNeich launches new Dual Therapy Stent for active vessel healing

OrbusNeich has announced the launch of its latest generation Dual Therapy Stent (DTS), the COMBO Plus.

21 Nov 2016

Study of new polymer-free DFS indicates non-inferior in-stent late lumen loss at nine-months

A first-in-human study of a new polymer-free drug-filled stent, which provides controlled drug elution from an internal lumen, indicated non-inferior in-stent late lumen loss at nine-months compared with historical zotarolimus-eluting stent (Resolute) data. In addition, there was no binary restenosis, and a high degree of early stent strut coverage with minimal malapposition.

2 Nov 2016

TCT 2016 features first report investigations on novel bioresorbable stents

The 28th annual Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation featured a number of first report investigations on novel stents that could become the next generation of bioresorbable stents in patients.

1 Nov 2016

ATS releases new clinical practice guidelines for diagnosis, management of LAM

The American Thoracic Society and the Japanese Respiratory Society have published new clinical practice guidelines for the diagnosis and management of lymphangioleiomyomatosis (LAM), a rare lung disease that primarily affects women of child-bearing age.

15 Sep 2016

PCI with polymer-free BA9 drug-coated stent better than bare metal stent in ACS patients

Patients with acute coronary syndromes (ACS) who are at high risk for bleeding have significantly lower rates of target lesion revascularisation and fewer adverse events after undergoing percutaneous coronary intervention (PCI) with a polymer-free biolimus-A (BA9) drug-coated stent than with those receiving a bare metal stent (BMS) in results from a sub-study of the LEADERS FREE trial reported for the first time in a late-breaker session at EuroPCR 2016.

17 May 2016

Rare disease day focuses on new approach to finding treatment

2,200 babies will be born in the UK on 29th February, of which 30 will die of a rare disease before they are five years old.

29 Feb 2016

Novartis announces FDA approval of Afinitor for progressive, nonfunctional neuroendocrine tumors of GI

Novartis today announced that the United States Food and Drug Administration approved Afinitor (everolimus) tablets for the treatment of adult patients with progressive, well-differentiated, nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin that are unresectable, locally advanced or metastatic.

26 Feb 2016

Sirolimus chemoprevention supported in organ transplant recipients

In solid-organ transplant recipients diagnosed with cancer post-transplant, treatment with sirolimus reduces the risk of developing a subsequent skin cancer, US investigators report in JAMA Dermatology.

29 Jan 2016

Patients with treatment-resistant autoimmune blood conditions may benefit from sirolimus

The immunosuppressant sirolimus is an effective and safe steroid-sparing therapy for children and young adults with highly treatment-resistant autoimmune blood conditions, according to a study published online today in Blood, the Journal of the American Society of Hematology.

27 Oct 2015

FDA awards research grants to boost product development for patients with rare diseases

The U.S. Food and Drug Administration today announced it has awarded 18 new research grants totaling more than $19 million to boost the development of products for patients with rare diseases, which affect the lives of nearly 30 million Americans.

11 Oct 2015

PRESTIGE study suggests novel target to prevent stent thrombosis

Recruitment of leukocytes is a hallmark of stent thrombosis, according to results from the PRESTIGE study presented today at ESC Congress and published in European Heart Journal. The findings suggest that immune cell mediated thrombotic processes may be a realistic target for novel therapies to prevent stent thrombosis.

1 Sep 2015

$Steroid-refractory chronic GVHD trial results ‘overestimate’ treatment efficacy$

Steroid-refractory chronic GVHD trial results ‘overestimate’ treatment efficacy

Trial results for patients with steroid-refractory chronic graft versus host have overestimated the efficacies of treatments, suggests a meta-analysis published in The Lancet Haematology.

24 Jul 2015

Mayo Clinic heart transplant surgeons present findings from three clinical studies at ISHLT 2015

Heart transplant surgeons from Mayo Clinic are presenting findings from three recent clinical studies involving heart transplant patients. The presentations took place during the 2015 International Society of Heart & Lung Transplant in Nice, France, on April 15-18.

21 Apr 2015

Bone marrow transplantation shows promising results among patients with severe sickle cell disease

Use of a lower intensity bone marrow transplantation method showed promising results among 30 patients (16-65 years of age) with severe sickle cell disease, according to a study in the July 2 issue of JAMA.

1 Jul 2014

STENTYS signs agreement to acquire assets of Cappella Peel Away

STENTYS, a medical technology company commercializing in Europe the world's first and only Self-Apposing® Stent to treat acute myocardial infarction (AMI), today announced the signing of the acquisition agreement of Cappella Peel Away Inc. (Delaware, USA) and its assets relating to a novel stent delivery system. The acquisition is subject to closing conditions.

5 Jun 2014

Micell Technologies presents DESSOLVE I and II trial data at EuroPCR conference

Micell Technologies, Inc. today announced that long-term clinical outcomes from its DESSOLVE I and II clinical trials were presented at the EuroPCR conference in Paris, France this week.

23 May 2014

Janssen submits sNDA to FDA for simeprevir in combination with sofosbuvir for treatment of HCV genotype 1 infection

Janssen Research & Development, LLC (Janssen) today announced it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for simeprevir, an NS3/4A protease inhibitor marketed as OLYSIO™ in the United States, in combination with the nucleotide analog NS5B polymerase inhibitor sofosbuvir developed by Gilead Sciences, Inc.

8 May 2014

Docs who treat patients with severe LAM face agonizing treatment decision

Doctors who treat patients with a severe and progressive respiratory disease called lymphangioleiomyomatosis (LAM) can face an agonizing treatment decision.

18 Apr 2014